BR112018069868A2 - modulador alostérico negativo do receptor metabotrópico de glutamato 5, usos de um nam, e método de tratamento ou atenuação de dano cerebral maduro - Google Patents
modulador alostérico negativo do receptor metabotrópico de glutamato 5, usos de um nam, e método de tratamento ou atenuação de dano cerebral maduroInfo
- Publication number
- BR112018069868A2 BR112018069868A2 BR112018069868A BR112018069868A BR112018069868A2 BR 112018069868 A2 BR112018069868 A2 BR 112018069868A2 BR 112018069868 A BR112018069868 A BR 112018069868A BR 112018069868 A BR112018069868 A BR 112018069868A BR 112018069868 A2 BR112018069868 A2 BR 112018069868A2
- Authority
- BR
- Brazil
- Prior art keywords
- nam
- attenuating
- glutamate
- treating
- brain damage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Pyridine Compounds (AREA)
- Electrotherapy Devices (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
a presente revelação se refere ao uso de moduladores alostéricos negativos (nams) do receptor metabotrópico de glutamato 5 (mglur5) no tratamento de um dano cerebral maduro, tal como dano após derrame.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/SE2016/050264 WO2017171594A1 (en) | 2016-03-30 | 2016-03-30 | Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages. |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018069868A2 true BR112018069868A2 (pt) | 2019-01-29 |
Family
ID=59964972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018069868A BR112018069868A2 (pt) | 2016-03-30 | 2016-03-30 | modulador alostérico negativo do receptor metabotrópico de glutamato 5, usos de um nam, e método de tratamento ou atenuação de dano cerebral maduro |
Country Status (12)
Country | Link |
---|---|
US (1) | US11033545B2 (pt) |
EP (1) | EP3436009B1 (pt) |
JP (2) | JP2019515892A (pt) |
KR (1) | KR102648875B1 (pt) |
CN (1) | CN108883104A (pt) |
AU (1) | AU2016400019A1 (pt) |
BR (1) | BR112018069868A2 (pt) |
CA (1) | CA3018375A1 (pt) |
EA (1) | EA201891948A1 (pt) |
MX (1) | MX2018011765A (pt) |
PL (1) | PL3436009T3 (pt) |
WO (1) | WO2017171594A1 (pt) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1210344T3 (da) * | 1999-08-19 | 2006-03-06 | Nps Pharma Inc | Heteropolycykliske forbindelser og anvendelser deraf som metabotrope glutamatreceptorantagonister |
MXPA03007513A (es) | 2001-02-21 | 2004-07-30 | Nps Pharma Inc | Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato. |
UA80888C2 (en) * | 2003-06-05 | 2007-11-12 | Hoffmann La Roche | Imidazole derivatives as glutmate receptor antagonists |
PT1756086E (pt) * | 2004-06-01 | 2008-08-08 | Hoffmann La Roche | Piridin-4-il-etinil-imidazoles e pirazoles como antagonistas dos receptores mglu5 |
US8609413B2 (en) * | 2007-12-11 | 2013-12-17 | Research Development Foundation | Neurons, astrocytes and oligodendrocytes differentiated from a mammalian pluripotent or neural stem cells exposed to a pyridine deriviative |
PE20150733A1 (es) | 2012-10-18 | 2015-05-17 | Hoffmann La Roche | Derivados de etinilo como moduladores de la actividad del receptor mglur5 |
KR101439203B1 (ko) * | 2013-03-29 | 2014-09-12 | 한림대학교 산학협력단 | Fk506 결합단백질 융합단백질과 피노밤을 포함하는 뇌 허혈손상 치료용 약제학적 조성물 |
ES2886859T3 (es) * | 2014-06-18 | 2021-12-21 | Csl Behring Gmbh | Terapia usando un inhibidor del factor xii en un trastorno neurotraumático |
KR101785155B1 (ko) * | 2015-09-22 | 2017-10-16 | 국립암센터 | Tim-3을 표적으로 하는 뇌손상 질환 치료용 조성물 및 이의 스크리닝 방법 |
JP2020534274A (ja) * | 2017-09-15 | 2020-11-26 | アゼヴァン ファーマシューティカルズ,インコーポレイテッド | 脳損傷を治療するための組成物及び方法 |
-
2016
- 2016-03-30 WO PCT/SE2016/050264 patent/WO2017171594A1/en active Application Filing
- 2016-03-30 EA EA201891948A patent/EA201891948A1/ru unknown
- 2016-03-30 CA CA3018375A patent/CA3018375A1/en active Pending
- 2016-03-30 BR BR112018069868A patent/BR112018069868A2/pt not_active Application Discontinuation
- 2016-03-30 KR KR1020187030975A patent/KR102648875B1/ko active IP Right Grant
- 2016-03-30 EP EP16897242.0A patent/EP3436009B1/en active Active
- 2016-03-30 CN CN201680084388.5A patent/CN108883104A/zh active Pending
- 2016-03-30 MX MX2018011765A patent/MX2018011765A/es unknown
- 2016-03-30 JP JP2018551874A patent/JP2019515892A/ja active Pending
- 2016-03-30 AU AU2016400019A patent/AU2016400019A1/en not_active Abandoned
- 2016-03-30 PL PL16897242.0T patent/PL3436009T3/pl unknown
- 2016-03-30 US US16/088,137 patent/US11033545B2/en active Active
-
2021
- 2021-02-10 JP JP2021019733A patent/JP7267326B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
EA201891948A1 (ru) | 2019-04-30 |
KR102648875B1 (ko) | 2024-03-15 |
US20190365753A1 (en) | 2019-12-05 |
EP3436009C0 (en) | 2024-03-06 |
KR20180123565A (ko) | 2018-11-16 |
EP3436009B1 (en) | 2024-03-06 |
JP2019515892A (ja) | 2019-06-13 |
JP2021098701A (ja) | 2021-07-01 |
CN108883104A (zh) | 2018-11-23 |
JP7267326B2 (ja) | 2023-05-01 |
CA3018375A1 (en) | 2017-10-05 |
EP3436009A4 (en) | 2019-11-27 |
US11033545B2 (en) | 2021-06-15 |
EP3436009A1 (en) | 2019-02-06 |
WO2017171594A1 (en) | 2017-10-05 |
MX2018011765A (es) | 2019-05-20 |
PL3436009T3 (pl) | 2024-05-06 |
AU2016400019A1 (en) | 2018-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502003A1 (en) | Cyclic sulfamide compounds and methods of using same | |
MX2021005887A (es) | Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina. | |
EP4282479A3 (en) | Use of pridopidine to treat depression or anxiety | |
PH12020500371A1 (en) | Spirocycle compounds and methods of making and using same | |
MY183637A (en) | Compounds and uses thereof for the modulation of hemoglobin | |
MX2015016438A (es) | Composiciones que comprenden tintes fotocromicos para el tratamiento de superficies. | |
MY191087A (en) | Compounds and uses thereof for the modulation of hemoglobin | |
WO2019040106A3 (en) | COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES | |
PH12020500372A1 (en) | Spirocycle compounds and methods of making and using same | |
UY36868A (es) | Composiciones para tratamiento de enfermedades mediadas por interleuquina 5 (il-5) | |
CL2016002827A1 (es) | Sistema para limpiar una región ocular, que comprende a un aplicardor que consiste de una primera y segunda camara, un elemento sellable que divide la primera y segunda camara, donde la segunda camara contiene una composicion ocular y b un surtidor kit y metodos de tratamientos. | |
BR112017015387A2 (pt) | composição em gel tópica, método de tratamento de uma infecção da pele, composição em gel oftálmica, e, método de tratamento de uma afecção infecciosa do olho ou pálpebra | |
BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
TR201900863T4 (tr) | Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması. | |
PH12017500615A1 (en) | Ophthalmic composition comprising cyclosporine and trehalose | |
SG10201804034QA (en) | Methods for treating hypotension | |
EA201690323A1 (ru) | Способы лечения заболеваний уха у детей | |
MX2017013047A (es) | Tratamiento de dolor. | |
MX355853B (es) | Composicion oftalmica para el tratamiento de infeccion ocular. | |
MX2015000884A (es) | Composicion odontologica de papaina en gel para el tratamiento atraumatico de caries y metodo para prepararla. | |
WO2013162981A3 (en) | Breast implant spacers for the treatment of periprosthetic breast implant infections | |
WO2019040105A3 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES | |
EP3549582A3 (en) | Novel capsazepine analogs for the treatment of cancer and other proliferative diseases | |
BR112018069868A2 (pt) | modulador alostérico negativo do receptor metabotrópico de glutamato 5, usos de um nam, e método de tratamento ou atenuação de dano cerebral maduro | |
MX2019004179A (es) | Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] |